The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Open accessAbstract
BACKGROUND: Somatic mutations in the Janus kinase 2 gene (JAK2) occur in many myeloproliferative neoplasms, but the molecular pathogenesis of myeloproliferative neoplasms with nonmutated JAK2 is obscure, and the diagnosis of these neoplasms remains a challenge. METHODS: We performed exome sequencing of samples obtained from 151 patients with myeloproliferative neoplasms. The mutation status of the gene encoding calreticulin (CALR) was assessed in an additional 1345 hematologic cancers, 1517 other cancers, and 550 controls. We established phylogenetic trees using hematopoietic colonies. We assessed calreticulin subcellular localization using immunofluorescence and flow cytometry. RESULTS: Exome sequencing identified 1498 mutations in 151 patients, with medians of 6.5, 6.5, and 13.0 mutations per patient in samples of polycythemia vera, essential thrombocythemia, and myelofibrosis, respectively. Somatic CALR mutations were found in 70 to 84% of samples of myeloproliferative neoplasms with nonmutated JAK2, in 8% of myelodysplasia samples, in occasional samples of other myeloid cancers, and in none of the other cancers. A total of 148 CALR mutations were identified with 19 distinct variants. Mutations were located in exon 9 and generated a +1 base-pair frameshift, which would result in a mutant protein with a novel C-terminal. Mutant calreticulin was observed in the endoplasmic reticulum without increased cell-surface or Golgi accumulation. Patients with myeloproliferative neoplasms carrying CALR mutations presented with higher platelet counts and lower hemoglobin levels than patients with mutated JAK2. Mutation of CALR was detected in hematopoietic stem and progenitor cells. Clonal analyses showed CALR mutations in the earliest phylogenetic node, a finding consistent with its role as an initiating mutation in some patients. CONCLUSIONS: Somatic mutations in the endoplasmic reticulum chaperone CALR were found in a majority of patients with myeloproliferative neoplasms with nonmutated JAK2. (Funded by the Kay Kendall Leukaemia Fund and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“But many of the most commonly seen mutations in CHIP are also recurrent drivers of AML 64, myelodysplastic syndrome (MDS) 65–67, myeloproliferative neoplasms 68, and certain lymphomas 69,70.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [68]
In the citing paper
“Calreticulin gene (CALR) mutations frequently occur in Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), primary myelofibrosis (PMF), and polycythemia vera (PV) [188–190].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [188]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
Self-citationA unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Couedic, J. P. L., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslová, H., Berger, R., Griscelli, A. B., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,542
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Patterns of somatic mutation in human cancer genomes
Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,062
Self-citationLevine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Self-citationClinical and biological implications of driver mutations in myelodysplastic syndromes
Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P., Yoon, C. J., Ellis, P., Wedge, D. C., Pellagatti, A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-518886 · Cited by 1,832
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Chao MP, 2010, Sci Transl Med, 2, 63ra94
Cited by
Sorted by citations
Items 201–300 of 1,002
Clinical insights into the origins of thrombosis in myeloproliferative neoplasms
Moliterno, A. R., Ginzburg, Y. Z., & Hoffman, R. (2020) · Blood · doi:10.1182/blood.2020008043 · Cited by 76
Palandri, F., Latagliata, R., Polverelli, N., Tieghi, A., Crugnola, M., Martino, B., Perricone, M., Breccia, M., Ottaviani, E., Testoni, N., et al. (2015) · Leukemia · doi:10.1038/leu.2015.87 · Cited by 76
Identification of unipotent megakaryocyte progenitors in human hematopoiesis
Miyawaki, K., Iwasaki, H., Jiromaru, T., Kusumoto, H., Yurino, A., Sugio, T., Uehara, Y., Odawara, J., Daitoku, S., Kunisaki, Y., et al. (2017) · Blood · doi:10.1182/blood-2016-09-741611 · Cited by 86
Stein, B. L., Oh, S. T., Berenzon, D. P., Hobbs, G. S., Kremyanskaya, M., Rampal, R. K., Abboud, C. N., Adler, K., Heaney, M. L., Jabbour, E. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.6474 · Cited by 75
Schischlik, F., Jäger, R., Rosebrock, F., Hug, E., Schuster, M. K., Holly, R., Fuchs, E., Feenstra, J. D. M., Bogner, E., Gisslinger, B., et al. (2019) · Blood · doi:10.1182/blood.2019000519 · Cited by 77
Rao, T. N., Hansen, N., Hilfiker, J., Rai, S., Majewska, J.-M., Leković, D., Gezer, D., Andina, N. D., Galli, S., Cassel, T., et al. (2019) · Blood · doi:10.1182/blood.2019000162 · Cited by 83
Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-β.
Agarwal, A. M., Morrone, K. A., Bartenstein, M., Zhao, Z. J., Verma, A. K., & Goel, S. (2016) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2306-9759.2016.02.03 · Cited by 77
Holmström, M. O., Riley, C. H., Svane, I. M., Hasselbalch, H. C., & Andersen, M. H. (2016) · Leukemia · doi:10.1038/leu.2016.233 · Cited by 74
Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface
Masubuchi, N., Araki, M., Yang, Y., Hayashi, E., Imai, M., Edahiro, Y., Hironaka, Y., Mizukami, Y., Kihara, Y., Takei, H., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0564-z · Cited by 73
Jeromin, S., Haferlach, T., Weißmann, S., Meggendorfer, M., Eder, C., Nadarajah, N., Alpermann, T., Kohlmann, A., Kern, W., Haferlach, C., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.119032 · Cited by 75
The importance of calcium in the regulation of megakaryocyte function
Buduo, C. A. D., Moccia, F. D., Battiston, M., Marco, L. D., Mazzucato, M., Moratti, R., Tanzi, F., & Balduini, A. (2014) · Haematologica · doi:10.3324/haematol.2013.096859 · Cited by 73
Rumi, E., Harutyunyan, A. S., Pietra, D., Feenstra, J. D. M., Casetti, I. C., Bellini, M., Them, N. C. C., Cavalloni, C., Ferretti, V. V., Milanesi, C., et al. (2014) · Blood · doi:10.1182/blood-2014-01-550434 · Cited by 72
Kreher, S., Ochsenreither, S., Trappe, R. U., Pabinger, I., Bergmann, F., Petrides, P. E., Koschmieder, S., Matzdorff, A. C., Tiede, A., Grießhammer, M., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2224-8 · Cited by 72
Venton, G., Courtier, F., Charbonnier, A., D’Incan, E., Saillard, C., Mohty, B., Mozziconacci, J., Birnbaum, D., Murati, A., Vey, N., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24973 · Cited by 77
How, J., Zhou, A. W., & Oh, S. T. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716680333 · Cited by 73
Andrades, Á., Peinado, P., Álvarez-Pérez, J. C., Sanjuán‐Hidalgo, J., García, D. J., Arenas, A. M., Matia‐González, A. M., & Medina, P. P. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01736-8 · Cited by 81
Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms
Jones, A. V., Ward, D., Lyon, M., Leung, W. C. Y., Callaway, A., Chase, A., Dent, C. L., White, H., Drexler, H. G., Nangalia, J., et al. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.11.019 · Cited by 71
Self-citationQi, X., Han, G., Guo, X., Stefano, V. D., Xu, K., Lu, Z., Xu, H., Mancuso, A., Zhang, W., Han, X., et al. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13815 · Cited by 70
Levy, G., Guglielmelli, P., Langmuir, P. B., & Constantinescu, S. N. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002838 · Cited by 70
Self-citationGenomic landscape of megakaryopoiesis and platelet function defects
Bianchi, E., Norfo, R., Pennucci, V., Zini, R., & Manfredini, R. (2016) · Blood · doi:10.1182/blood-2015-07-607952 · Cited by 70
Single-cell analysis based dissection of clonality in myelofibrosis
Mylonas, E., Yoshida, K., Frick, M., Hoyer, K., Christen, F., Kaeda, J., Obenaus, M., Noerenberg, D., Hennch, C., Chan, W., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13892-x · Cited by 72
Hultcrantz, M. L., Landtblom, A. R., Andréasson, B., Samuelsson, J., Dickman, P. W., Kristinsson, S. Y., Björkholm, M., & Andersson, T. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13019 · Cited by 69
Primary thrombocytosis in children
Kucine, N., Chastain, K. M., Mahler, M., & Bussel, J. B. (2014) · Haematologica · doi:10.3324/haematol.2013.092684 · Cited by 69
Ianotto, J., Chauveau, A., Boyer‐Perrard, F., Gyan, E., Laribi, K., Cony‐Makhoul, P., Demory, J., Renzis, B. D., Dosquet, C., Rey, J., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.181297 · Cited by 74
Ruxolitinib: A Review of Its Use in Patients with Myelofibrosis
Plosker, G. L. (2015) · Drugs · doi:10.1007/s40265-015-0351-8 · Cited by 71
Genomics of Myeloproliferative Neoplasms
Zoi, K., & Cross, N. C. P. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7968 · Cited by 73
Self-citationPoisson, J., Plessier, A., Kiladjian, J., Turón, F., Cassinat, B., Andreoli, A., de Raucourt, E., Goria, O., Zekrini, K., Bureau, C., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.04.021 · Cited by 68
Andersen, M., Sajid, Z., Pedersen, R. K., Gudmand‐Hoeyer, J., Ellervik, C., Skov, V., Kjær, L., Pallisgaard, N., Kruse, T. A., Thomassen, M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183620 · Cited by 68
Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells
Wang, X., Hu, C. S., Petersen, B. E., Qiu, J., Ye, F., Houldsworth, J., Eng, K. H., Huang, F., & Hoffman, R. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018022012 · Cited by 69
Álvarez‐Larrán, A., Ancochea, Á., Garcia, M., Climent, F., García‐Pallarols, F., Angona, A., Senín, A., Barranco, C., Martinez-Aviles, L. M., Serrano, S., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12990 · Cited by 67
Hu, X., Feng, C., Zhou, Y., Harrison, A., & Chen, M. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab737 · Cited by 73
Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations
Assaf, C. A., Obbergh, F. V., Billiet, J., Lierman, E., Devos, T., Graux, C., Hervent, A.-S., Emmerechts, J., Tousseyn, T., Paepe, P. D., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.118299 · Cited by 67
Biology and therapeutic targeting of molecular mechanisms in MPNs
How, J., Garcia, J. S., & Mullally, A. (2022) · Blood · doi:10.1182/blood.2022017416 · Cited by 75
MEGAKARYOCYTE CONTRIBUTION TO BONE MARROW FIBROSIS: MANY ARROWS IN THE QUIVER
Malara, A., Abbonante, V., Zingariello, M., Migliaccio, A. R., & Balduini, A. (2018) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2018.068 · Cited by 72
The complex roles of efferocytosis in cancer development, metastasis, and treatment
Tajbakhsh, A., Gheibi hayat, S. M., Movahedpour, A., Savardashtaki, A., Loveless, R., Barreto, G. E., Teng, Y., & Sahebkar, A. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111776 · Cited by 64
Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation
Araki, M., Yang, Y., Imai, M., Mizukami, Y., Kihara, Y., Sunami, Y., Masubuchi, N., Edahiro, Y., Hironaka, Y., Osaga, S., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0181-2 · Cited by 64
Panagiota, V., Thol, F. R., Markus, B., Fehse, B., Alchalby, H., Badbaran, A., Lehmann, U., Koenecke, C., Shahswar, R., Chaturvedi, A., et al. (2014) · Leukemia · doi:10.1038/leu.2014.66 · Cited by 64
McGaffin, G., Harper, K., Stirling, D., & McLintock, L. A. (2014) · British Journal of Haematology · doi:10.1111/bjh.12969 · Cited by 64
Calreticulin, a therapeutic target?
Eggleton, P., Bremer, E., Dudek, E., & Michalak, M. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1164695 · Cited by 64
Germline RBBP6 mutations in familial myeloproliferative neoplasms
Harutyunyan, A. S., Giambruno, R., Krendl, C., Stukalov, A., Klampfl, T., Berg, T., Chen, D., Feenstra, J. D. M., Jäger, R., Gisslinger, B., et al. (2015) · Blood · doi:10.1182/blood-2015-09-668673 · Cited by 67
Czech, J., Cordua, S., Weinbergerová, B., Baumeister, J., Crepcia, A., Han, L., Maié, T., Costa, I. G., Denecke, B., Maurer, A., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0295-6 · Cited by 64
Grauslund, J. H., Holmström, M. O., Jørgensen, N. G. D., Klausen, U., Weis-Banke, S. E., Fassi, D. E., Schöllkopf, C., Clausen, M. B., Gjerdrum, L. M. R., Breinholt, M. F., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.637420 · Cited by 64
Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 69
Springuel, L., Renauld, J., & Knoops, L. (2015) · Haematologica · doi:10.3324/haematol.2015.132142 · Cited by 64
Long‐term outcomes following percutaneous hepatic vein recanalization for Budd–Chiari syndrome
Tripathi, D., Sunderraj, L., Vemala, V., Mehrzad, H., Zia, Z., Mangat, K. S., West, R. J., Chen, F. E., Elias, E., & Olliff, S. P. (2016) · Liver International · doi:10.1111/liv.13180 · Cited by 63
Broadbent, A. (2012) · Preventive Medicine · doi:10.1016/s0091-7435(12)00530-0 · Cited by 63
Kramann, R., & Schneider, R. K. (2018) · Blood · doi:10.1182/blood-2018-02-834820 · Cited by 62
Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis
Desterke, C., Martinaud, C., Ruzehaji, N., & Bousse‐Kerdilès, M. L. (2015) · Mediators of Inflammation · doi:10.1155/2015/415024 · Cited by 67
Kollmann, K., Warsch, W., Arias, C. G., Nice, F. L., Avezov, E., Milburn, J. V., Li, J., Dimitropoulou, D., Biddie, S. C., Wang, M., et al. (2016) · Leukemia · doi:10.1038/leu.2016.280 · Cited by 62
Self-citationLussana, F., Carobbio, A., Salmoiraghi, S., Guglielmelli, P., Vannucchi, A. M., Bottazzi, B., Leone, R., Mantovani, A., Barbui, T., & Rambaldi, A. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0425-z · Cited by 62
Self-citationReview article: a multidisciplinary approach to the diagnosis and management of Budd‐Chiari syndrome
Khan, F., Armstrong, M. J., Mehrzad, H., Chen, F. E., Desley, N., Brown, R. M., Cain, O. L., & Tripathi, D. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15149 · Cited by 62
Zhang, Y., Zhou, Y., Wang, Y., Teng, G., Li, D., Wang, Y., Du, C., Chen, Y., Zhang, H., Li, Y., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.2886 · Cited by 62
The Molecular Genetics of Myeloproliferative NeoplasmsPreprint
Marneth, A. E., & Mullally, A. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034876 · Cited by 65
Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms
Hoermann, G., Greiner, G., & Valent, P. (2015) · Mediators of Inflammation · doi:10.1155/2015/869242 · Cited by 61
Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia
Togasaki, E., Takeda, J., Yoshida, K., Shiozawa, Y., Takeuchi, M., Oshima, M., Saraya, A., Iwama, A., Yokote, K., Sakaida, E., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.36 · Cited by 61
ASXL1 mutation in clonal hematopoiesis
Fujino, T., & Kitamura, T. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.01.002 · Cited by 64
Masselli, E., Pozzi, G., Gobbi, G., Merighi, S., Gessi, S., Vitale, M., & Carubbi, C. (2020) · Cells · doi:10.3390/cells9092136 · Cited by 63
Calreticulin: Endoplasmic reticulum Ca 2+ gatekeeper
Michalak, M. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17839 · Cited by 60
Enblom‐Larsson, A., Lindskog, E., Hasselbalch, H. C., Hersby, D. S., Bak, M., Tetu, J., Girodon, F., & Andréasson, B. (2015) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.03.009 · Cited by 60
The role of mutations in epigenetic regulators in myeloid malignancies
Woods, B. A., & Levine, R. L. (2014) · Immunological Reviews · doi:10.1111/imr.12246 · Cited by 63
In utero origin of myelofibrosis presenting in adult monozygotic twins
Sousos, N., Leathlobhair, M. N., Karali, C. S., Louka, E., Bienz, N., Royston, D. J., Clark, S., Hamblin, A. D., Howard, K., Mathews, V., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01793-4 · Cited by 60
Self-citationTargeting the CALR interactome in myeloproliferative neoplasms
Pronier, E., Cifani, P., Merlinsky, T. R., Berman, K. B., Somasundara, A. V. H., Rampal, R. K., LaCava, J., Wei, K. E., Pastore, F., Mååg, J. L. V., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122703 · Cited by 61
EDA fibronectin–TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis
Malara, A., Gruppi, C., Abbonante, V., Cattaneo, D., Marco, L. D., Massa, M., Iurlo, A., Gianelli, U., Balduini, C. L., Tira, M. E., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20181074 · Cited by 63
García‐García, A., de Castillejo, C. L. F., & Méndez‐Ferrer, S. (2015) · Immunology Letters · doi:10.1016/j.imlet.2015.06.020 · Cited by 61
JAK Inhibitor in CALR-Mutant Myelofibrosis
Passamonti, F., Caramazza, D., & Maffioli, M. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1400499 · Cited by 60
Order Matters: The Order of Somatic Mutations Influences Cancer EvolutionPreprint
Kent, D. G., & Green, A. R. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a027060 · Cited by 61
Self-citationCalreticulin gene exon 9 frameshift mutations in patients with thrombocytosis
Chi, J., Nicolaou, K. A., Nicolaidou, V., Koumas, L., Mitsidou, A., Pierides, C., Manoloukos, M., Barbouti, K., Melanthiou, F., Prokopiou, C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.382 · Cited by 58
CALR mutations and a new diagnostic algorithm for MPN
Tefferi, A., & Pardanani, A. D. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.16 · Cited by 58
Kuo, F. C., Mar, B. G., Lindsley, R. C., & Lindeman, N. I. (2017) · Blood · doi:10.1182/blood-2017-03-734533 · Cited by 58
McKerrell, T., Park, N., Chi, J., Collord, G., Moreno-Rodriguez, T., Ponstingl, H., Dias, J. M. L., Gerasimou, P., Melanthiou, K., Prokopiou, C., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017007047 · Cited by 59
Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR?
Cilloni, D., Petiti, J., Rosso, V., Andreani, G., Dragani, M., Fava, C., & Saglio, G. N. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092249 · Cited by 58
Salati, S., Genovese, E., Carretta, C., Zini, R., Bartalucci, N., Prudente, Z., Pennucci, V., Ruberti, S., Rossi, C., Rontauroli, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46843-z · Cited by 59
Self-citationMosca, M., Hermange, G., Tisserand, A., Noble, R., Marzac, C., Marty, C., Le Sueur, C., Campario, H., Vertenoeil, G., El-Khoury, M., et al. (2021) · Blood · doi:10.1182/blood.2021010986 · Cited by 57
The role of JAK2 inhibitors in MPNs 7 years after approval
Passamonti, F., & Maffioli, M. (2018) · Blood · doi:10.1182/blood-2018-01-791491 · Cited by 57
Somatic mutations of calreticulin in myeloproliferative neoplasms
Imai, M., Araki, M., & Komatsu, N. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2246-9 · Cited by 56
Patnaik, M. M., & Tefferi, A. (2021) · American Journal of Hematology · doi:10.1002/ajh.26090 · Cited by 57
Clonal hematopoiesis and hematological malignancy
Dunn, W. G., McLoughlin, M. A., & Vassiliou, G. S. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180065 · Cited by 63
Mpl Traffics to the Cell Surface Through Conventional and Unconventional Routes
Cleyrat, C., Darehshouri, A., Steinkamp, M. P., Vilaine, M., Boassa, D., Ellisman, M. H., Hermouet, S., & Wilson, B. S. (2014) · Traffic · doi:10.1111/tra.12185 · Cited by 56
Rufino‐Palomares, E. E., Pérez‐Jiménez, A., Reyes‐Zurita, F. J., Garcı́a-Salguero, L., Mokhtari, K., Herrera-Merchan, A., Medina, P. P., Peragón, J., & Lupiáñez, J. A. (2015) · Current Organic Chemistry · doi:10.2174/1385272819666150119225952 · Cited by 56
Update from the latest WHO classification of MPNs: a user’s manual
Passamonti, F., & Maffioli, M. (2016) · Hematology · doi:10.1182/asheducation-2016.1.534 · Cited by 56
Impact of molecular residual disease post allografting in myelofibrosis patients
Wolschke, C., Badbaran, A., Zabelina, T., Christopeit, M., Ayuk, F. A., Triviai, I., Zander, A., Alchalby, H., Bacher, U., Fehse, B., et al. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.157 · Cited by 56
Myeloproliferative neoplasms: from origins to outcomes
Nangalia, J., & Green, A. R. (2017) · Hematology · doi:10.1182/asheducation-2017.1.470 · Cited by 58
Self-citationThe Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep
Accurso, V., Santoro, M., Mancuso, S., Napolitano, M., Carlisi, M., Mattana, M., Russo, C., Stefano, A. D., Sirocchi, D., & Siragusa, S. M. (2020) · Clinical Medicine Insights Blood Disorders · doi:10.1177/2634853520978210 · Cited by 56
Structure of the thrombopoietin-MPL receptor complex is a blueprint for biasing hematopoiesis
Tsutsumi, N., Masoumi, Z. T., James, S. C., Tucker, J. A., Winkelmann, H., Grey, W. E., Picton, L. K., Moss, L., Wilson, S. C., Caveney, N. A., et al. (2023) · Cell · doi:10.1016/j.cell.2023.07.037 · Cited by 55
Smoking as a contributing factor for development of polycythemia vera and related neoplasms
Hasselbalch, H. C. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.09.002 · Cited by 55
Broséus, J., Lippert, É., Harutyunyan, A. S., Jeromin, S., Zipperer, E., Florensa, L., Feenstra, J. D. M., Haferlach, T., Germing, U., Luño, E., et al. (2014) · Leukemia · doi:10.1038/leu.2014.49 · Cited by 58
Pizzi, M., Silver, R. T., Barel, A., & Orazi, A. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.93 · Cited by 55
Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia
Elala, Y. C., Lasho, T. L., Gangat, N., Finke, C. M., Barraco, D., Haider, M., Hussein, A. K. A., Hanson, C. A., Ketterling, R. P., Pardanani, A. D., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24338 · Cited by 55
Wijeyesakere, S. J., Bedi, S., Huynh, D. A. H., & Raghavan, M. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502122 · Cited by 57
Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions
Shammo, J. M., & Stein, B. L. (2016) · Hematology · doi:10.1182/asheducation-2016.1.552 · Cited by 57
Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis
Plo, I., Bellanné‐Chantelot, C., Mosca, M., Mazzi, S., Marty, C., & Vainchenker, W. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00234 · Cited by 62
Harrison, C. N., Butt, N. M., Campbell, P. J., Conneally, E., Drummond, M. W., Green, A. R., Murrin, R. J. A., Radia, D. H., Mead, A. J., Reilly, J. T., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12986 · Cited by 54
Self-citationClinical Significance of DNA Variants in Chronic Myeloid Neoplasms
McClure, R. F., Ewalt, M. D., Crow, J., Temple‐Smolkin, R., Pullambhatla, M., Sargent, R. L., & Kim, A. S. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.07.002 · Cited by 54
Grabek, J., Straube, J., Bywater, M. J., & Lane, S. (2020) · Cells · doi:10.3390/cells9081901 · Cited by 60
Chen, C., Gau, J., Chou, H.-J., You, J., Huang, C., Chen, Y. Y., Lung, J., Chou, Y. S., Leu, Y. W., Lu, C., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2151-8 · Cited by 53
Dunbar, A. J., Kim, D., Lü, M., Farina, M., Bowman, R. L., Yang, J. L., Park, Y. C., Karzai, A., Xiao, W., Zaroogian, Z., et al. (2023) · Blood · doi:10.1182/blood.2022015418 · Cited by 57
Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion
Heaton, W. L., Senina, A. V., Pomicter, A. D., Salama, M. E., Clair, P. M., Yan, D., Bell, R. N., Gililland, J. M., Prchal, J. T., O’Hare, T., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0131-z · Cited by 56
Hofmann, I., Geer, M. J., Vögtle, T., Crispin, A., Campagna, D. R., Barr, A., Calicchio, M. L., Heising, S., van Geffen, J. P., Kuijpers, M. J. E., et al. (2018) · Blood · doi:10.1182/blood-2017-08-802769 · Cited by 53
Anderson, L. A., James, G., Duncombe, A. S., Mesa, R. A., Scherber, R. M., Dueck, A. C., de Vocht, F., Clarke, M. J., & McMullin, M. F. (2015) · American Journal of Hematology · doi:10.1002/ajh.24098 · Cited by 52
Heterogeneity in myeloproliferative neoplasms: Causes and consequences
O’Sullivan, J., & Mead, A. J. (2018) · Advances in Biological Regulation · doi:10.1016/j.jbior.2018.11.007 · Cited by 58
Metadata
- Authors
- Nangalia, J., Massie, C. E., Baxter, E. J., Nice, F. L., Gundem, G., Wedge, D. C., Avezov, E., Li, J., Kollmann, K., Kent, D. G., Aziz, A., Godfrey, A. L., Hinton, J., Martincorena, I., Van Loo, P., Jones, A. V., Guglielmelli, P., Tarpey, P., Harding, H. P., Fitzpatrick, J. D., Goudie, C. T., Ortmann, C. A., Loughran, S. J., Raine, K., Jones, D. R., Butler, A. P., Teague, J. W., O'Meara, S., McLaren, S., Bianchi, M., Silber, Y., Dimitropoulou, D., Bloxham, D., Mudie, L., Maddison, M., Robinson, B., Keohane, C., Maclean, C., Hill, K., Orchard, K., Tauro, S., Du, M.-Q., Greaves, M., Bowen, D., Huntly, B. J. P., Harrison, C. N., Cross, N. C. P., Ron, D., Vannucchi, A. M., Papaemmanuil, E., Campbell, P. J., & Green, A. R.
- ORCID
- Nangalia, J.
- Massie, C.E.
- Baxter, E.J.
- Nice, F.L.
- Gundem, G.
- Wedge, D.C.
- Avezov, E.
- Kollmann, K.
- Kent, D.G.
- Godfrey, A.L.
- Hinton, J.
- Martincorena, I.
- Jones, A.V.
- Guglielmelli, P.
- Tarpey, P.
- Harding, H.P.
- Fitzpatrick, J.D.
- Loughran, S.J.
- Raine, K.
- Jones, D.R.
- Teague, J.W.
- McLaren, S.
- Hill, K.
- Orchard, K.
- Du, M.-Q.
- Greaves, M.
- Bowen, D.
- Huntly, B.J.P.
- Harrison, C.N.
- Cross, N.C.P.
- Ron, D.
- Vannucchi, A.M.
- Papaemmanuil, E.
- Campbell, P.J.
- Green, A.R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-12-19
- Volume
- 369
- Issue
- 25
- Pages
- 2391-2405
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3966280
- OpenAlex
- W2138709799
- Cited by
- 1,756
- References
- 40
- Citations by year
- 2026: 64 · 2025: 59 · 2024: 72 · 2023: 90 · 2022: 112 · 2021: 133 · 2020: 125 · 2019: 124 · 2018: 130 · 2017: 181 · 2016: 208 · 2015: 239 · 2014: 208 · 2013: 7
- FWCI
- 108.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- University of Salford Institutional Repository (University of Salford) (submittedVersion, cc-by)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Leukemia and Lymphoma Society
- Leukemia and Lymphoma Research
- University of Salford Manchester
- Wellcome Trust (079249, 100140, 093867, 084812)
- University Hospital Southampton NHS Foundation Trust
- Cancer Research UK (12526, 12765, 15488)
- National Institute for Health and Care Research (NF-SI-0512-10079)
- Kay Kendall Leukaemia Fund
- University of Southampton
- KU Leuven
- Università degli Studi di Firenze
- Associazione Italiana per la Ricerca sul Cancro
- Vlaamse regering
- Canadian Institutes of Health Research
- Medical Research Council
- Cambridge Institute for Medical Research, University of Cambridge
- NIHR Cambridge Biomedical Research Centre
- Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze
- Topics
- Health Sciences › Medicine › Hematology › Myeloproliferative Neoplasms: Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- calreticulin, CALR mutation, myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, myelofibrosis, myelodysplastic syndrome, endoplasmic reticulum chaperone, clonal evolution, hematopoietic stem and progenitor cells, somatic mutations
- MeSH terms
- Amino Acid Sequence, Bone Marrow Diseases, Exons, Humans, Leukemia, Myeloid, Molecular Sequence Data, Mutation, Myelodysplastic Syndromes, Neoplasms, Thrombocythemia, Essential, Polymerase Chain Reaction, Sequence Analysis, DNA, Calreticulin, Janus Kinase 2, Primary Myelofibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
